Gujarat Cancer Society Medical College and Research Center, Ahmedabad, Gujarat, India.
Gujarat Cancer Society Medical College and Research Center, Ahmedabad, Gujarat, India.
Indian J Tuberc. 2024;71 Suppl 1:S25-S28. doi: 10.1016/j.ijtb.2023.06.001. Epub 2023 Jun 7.
This study is conducted from year 2019-2022 in Gujarat Cancer Society medical college and research center, Ahmedabad. Out of total 275 patients on drug resistant TB regimen (all oral longer, shorter injectable and mono H) seen in opd, 55 patients presented with adverse drug reaction. Most commonly affected age group was 20-40 yr old. During the course of treatment 32.7% required hospitalization, of which 29% were admitted in ward, rest required ICU care. Maximum ADR occurred in first 30 days of starting ATT. Drug had to be withdrawn in 41.81% and in 32.7%, offending agent was withdrawn permanently. There was no mortality during the study.
这项研究于 2019 年至 2022 年在古吉拉特邦癌症协会医学研究所和研究中心进行。在门诊接受耐药结核病方案（所有口服更长、更短注射和单 H）治疗的 275 名患者中，有 55 名出现药物不良反应。最常见的受影响年龄组为 20-40 岁。在治疗过程中，32.7%需要住院治疗，其中 29%住院，其余需要 ICU 护理。最大的 ADR 发生在开始 ATT 的前 30 天。41.81%的患者需要停药，32.7%的患者永久停用了有问题的药物。在研究期间没有死亡。
